{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:39:46Z","timestamp":1792607986318,"version":"4.5.0"},"reference-count":18,"publisher":"MyJove Corporation","issue":"197","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/65467","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T20:00:22Z","timestamp":1688760022000},"source":"Crossref","is-referenced-by-count":1,"title":["Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1\/PD-L1 Interaction"],"prefix":"10.3791","author":[{"given":"Jay","family":"Overholser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin T. P.","family":"Kaumaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2217\/fon-2020-0224","type":"journal-article","article-title":"B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine","volume":"16","author":"Kaumaya","year":"2020","unstructured":"Kaumaya, P. T. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology. 16 (23), 1767-1791 (2020).","journal-title":"Future Oncology"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/ph15030335","type":"journal-article","article-title":"Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4","volume":"15","author":"Pandey","year":"2022","unstructured":"Pandey, P. et al. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals. 15 (3), 335 (2022).","journal-title":"Pharmaceuticals"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"826566","DOI":"10.3389\/fonc.2022.826566","type":"journal-article","article-title":"Preclinical studies of a novel human PD-1 B-cell peptide cancer vaccine PD1-Vaxx from BALB\/c mice to beagle dogs and to non-human primates (cynomolgus monkeys)","volume":"12","author":"Guo","year":"2022","unstructured":"Guo, L., Overholser, J., Good, A. J., Ede, N. J., Kaumaya, P. T. P. Preclinical studies of a novel human PD-1 B-cell peptide cancer vaccine PD1-Vaxx from BALB\/c mice to beagle dogs and to non-human primates (cynomolgus monkeys). Frontiers in Oncology. 12, 826566 (2022).","journal-title":"Frontiers in Oncology"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2217\/fon.15.52","type":"journal-article","article-title":"Nivolumab: Targeting PD-1 to bolster antitumor immunity","volume":"11","author":"Brahmer","year":"2015","unstructured":"Brahmer, J. R., Hammers, H., Lipson, E. J. Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncology. 11 (9), 1307-1326 (2015).","journal-title":"Future Oncology"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/21645515.2017.1403694","type":"journal-article","article-title":"Product review on the Anti-PD-L1 antibody atezolizumab","volume":"14","author":"Shah","year":"2018","unstructured":"Shah, N. J., Kelly, W. J., Liu, S. V., Choquette, K., Spira, A. Product review on the Anti-PD-L1 antibody atezolizumab. Human Vaccines & Immunotherapeutics. 14 (2), 269-276 (2018).","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","type":"journal-article","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R., Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. The New England Journal of Medicine. 378 (2), 158-168 (2018).","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1080\/21645515.2015.1026495","type":"journal-article","article-title":"A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy","volume":"11","author":"Kaumaya","year":"2015","unstructured":"Kaumaya, P. T. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Human Vaccines & Immunotherapeutics. 11 (6), 1368-1386 (2015).","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41416-021-01342-9","type":"journal-article","article-title":"First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: Exploiting future novel synergistic vaccine combinations","volume":"125","author":"Guo","year":"2021","unstructured":"Guo, L., Kaumaya, P. T. P. First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: Exploiting future novel synergistic vaccine combinations. British Journal of Cancer. 125. (2), 152-154 (2021).","journal-title":"British Journal of Cancer"},{"issue":"14","key":"ref9","first-page":"3782","type":"journal-article","article-title":"Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine","volume":"60","author":"Dakappagari","year":"2000","unstructured":"Dakappagari, N. K., Douglas, D. B., Triozzi, P. L., Stevens, V. C., Kaumaya, P. T. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Research. 60 (14), 3782-3789 (2000).","journal-title":"Cancer Research"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1074\/jbc.M411020200","type":"journal-article","article-title":"Conformational HER-2\/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities","volume":"280","author":"Dakappagari","year":"2005","unstructured":"Dakappagari, N. K. et al. Conformational HER-2\/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. The Journal of Biological Chemistry. 280 (1), 54-63 (2005).","journal-title":"The Journal of Biological Chemistry"},{"issue":"31","key":"ref11","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1200\/JCO.2009.22.3883","type":"journal-article","article-title":"Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous Tcell epitope in patients with metastatic and\/or recurrent solid tumors","volume":"27","author":"Kaumaya","year":"2009","unstructured":"Kaumaya, P. T. et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous Tcell epitope in patients with metastatic and\/or recurrent solid tumors. Journal of Clinical Oncology. 27 (31), 5270-5277 (2009).","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-18-3997","type":"journal-article","article-title":"Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors","volume":"25","author":"Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab, T. et al. Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors. Clinical Cancer Research. 25. (12),3495-3507 (2019).","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"1818437","DOI":"10.1080\/2162402X.2020.1818437","type":"journal-article","article-title":"Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab\/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model","volume":"9","author":"Kaumaya","year":"2020","unstructured":"Kaumaya, P. T. P., Guo, L., Overholser, J., Penichet, M. L., Bekaii-Saab, T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab\/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology. 9 (1), 1818437 (2020).","journal-title":"Oncoimmunology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"2127691","DOI":"10.1080\/2162402X.2022.2127691","type":"journal-article","article-title":"A newly discovered PD-L1 B_cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)","volume":"11","author":"Guo","year":"2022","unstructured":"Guo, L., Overholser, J., Darby, H., Ede, N. J., Kaumaya, P. T. P. A newly discovered PD-L1 B_cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). Oncoimmunology. 11 .(1), 2127691 (2022).","journal-title":"Oncoimmunology"},{"key":"ref15","volume-title":"Luminex Corporation. The xMAP\u00ae Cookbook, 5th edition","author":"Angeloni","year":"2022","unstructured":"Angeloni, S., Das, S., De Jager, W., Dunbar, S., Luminex Corporation. The xMAP\u00ae Cookbook, 5th edition. At <https:\/\/info.luminexcorp.com\/en-us\/research\/download-the-xmap-cookbook?utm_referrer=https%3A%2F%2Fwww.luminexcorp.com%2F> (2022)."},{"key":"ref16","article-title":"MagPlex\u00ae Microspheres Documentation. Product information sheet","volume-title":"Luminex Corporation","year":"2014","unstructured":"Luminex Corporation. MagPlex\u00ae Microspheres Documentation. Product information sheet. At <https:\/\/www.luminexcorp.com\/magplex-microspheres\/#overview> (2014)."},{"key":"ref17","type":"book","volume-title":"Estimation of cell number by hemocytometry counting","author":"Green","year":"2019","unstructured":"Green, M. R., Sambrook, J. Estimation of cell number by hemocytometry counting. Cold Spring Harbor Protocols. 2019 (11) (2019)."},{"key":"ref18","article-title":"Selecting the Detection System - Colorimetric, Fluorescent, Luminescent Methods for ELISA Assays","volume-title":"Corning Inc","author":"Gibbs","year":"2019","unstructured":"Gibbs, J., Vessels, M., Rothenberg, M., Corning Inc. Selecting the Detection System - Colorimetric, Fluorescent, Luminescent Methods for ELISA Assays. At https:\/\/www.corning.com\/catalog\/cls\/documents\/application-notes\/CLS-DD-AN-458.pdf> (2019)."}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/65467\/magnetic-fluorescent-bead-based-dual-reporter-flow-analysis-pdl1-vaxx","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:58:19Z","timestamp":1792605499000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/65467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":18,"journal-issue":{"issue":"197","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3791\/65467","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}